Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$624.21 USD
+3.79 (0.61%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $623.39 -0.82 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$624.21 USD
+3.79 (0.61%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $623.39 -0.82 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Grows on New Buyouts Amid Tough Competition
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of FEI Company already adds capabilities to its analytical instruments portfolio. Also, solid cash in hand enables the company to yield fat returns to investors.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
Thermo Fisher (TMO) Beats on Q4 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high on strength in all segments in Q4.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Are Interest Rates Really Going Up?
by Sheraz Mian
The odds of interest rates going up meaningfully are not as far-fetched as many likely in the market believe.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Top Research Reports for Microsoft, Intel & UnitedHealth
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Intel (INTC) and UnitedHealth (UNH).
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.
Global In Vitro Diagnostic Market Booms: Stocks in Focus
by Zacks Equity Research
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
Thermo Fisher (TMO) Beats on Q3 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high in Q3 banking on its analytical instruments segment in particular.
MedTech Stocks (BAX, VAR, TMO, LH) Earnings Preview: What You Should Know
by Zacks Equity Research
The Medical Product space has been a precarious game for the Republicans since day one, courtesy of President Trump's repeated failure to repeal and replace Obamacare.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
by Zacks Equity Research
The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Why Thermo Fisher (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.
What's in Store for Penumbra (PEN) Stock in Q3 Earnings?
by Zacks Equity Research
Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.
Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.
Will Invisalign Drive Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is poised to gain from strength in the Invisalign space in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.